Nilotinib
- Generic Name
- Nilotinib
- Brand Names
- Tasigna, Nilotinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C28H22F3N7O
- CAS Number
- 641571-10-0
- Unique Ingredient Identifier
- F41401512X
- Background
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), anoth...
- Indication
For the potential treatment of various leukemias, including chronic myeloid leukemia (CML).
- Associated Conditions
- Accelerated Phase Chronic Myelogenous Leukemia (CML), Chronic Phase Chronic Myeloid Leukemia, Newly diagnosed, chronic phase Chronic myeloid leukemia, Refractory Gastrointestinal stromal tumor
- Associated Therapies
- -
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
- Conditions
- Interventions
- First Posted Date
- 2010-08-11
- Last Posted Date
- 2014-05-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 23
- Registration Number
- NCT01179737
- Locations
- 🇨🇭
Novartis Investigative Site, Zurich, Switzerland
Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.
- Conditions
- Interventions
- First Posted Date
- 2010-07-22
- Last Posted Date
- 2011-02-08
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 25
- Registration Number
- NCT01168050
- Locations
- 🇫🇷
Hôpital Saint-Louis, Paris, France
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
- Conditions
- Interventions
- First Posted Date
- 2010-07-02
- Last Posted Date
- 2020-04-15
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 33
- Registration Number
- NCT01155817
- Locations
- 🇨🇦
Gordon and Leslie Diamond Health Care Centre Hematology Administration, Vancouver, British Columbia, Canada
🇺🇸Stanford University School of Medicine, Stanford, California, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas
- First Posted Date
- 2010-06-09
- Last Posted Date
- 2020-05-05
- Lead Sponsor
- David Piccioni, M.D., Ph.D
- Target Recruit Count
- 38
- Registration Number
- NCT01140568
- Locations
- 🇺🇸
The Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations
- Conditions
- Interventions
- First Posted Date
- 2010-05-26
- Last Posted Date
- 2021-05-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 3
- Registration Number
- NCT01131325
- Locations
- 🇺🇸
Comprehensive Cancer Centers of Nevada CCC of Nevada (1), Las Vegas, Nevada, United States
🇺🇸Cancer Center of the High Plains, Amarillo, Texas, United States
🇺🇸Baylor Health Care System/Sammons Cancer Center Dept. of Sammons Cancer (2), Dallas, Texas, United States
A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
- First Posted Date
- 2010-05-20
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 6
- Registration Number
- NCT01126892
- Locations
- 🇻🇪
Banco Municipal de Sangre, Caracas, Venezuela
🇨🇴Hospital San José, Bogotá, Colombia, Bogota, Colombia
Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
- First Posted Date
- 2010-04-27
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2
- Registration Number
- NCT01110668
- Locations
- 🇹🇷
Novartis Investigative Site, Izmir, Turkey
Study of Nilotinib in Metastatic Melanoma With KIT Aberrations
- First Posted Date
- 2010-04-07
- Last Posted Date
- 2015-12-29
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 33
- Registration Number
- NCT01099514
- Locations
- 🇰🇷
Samsung Cancer Center, Seoul, Korea, Republic of
Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
- Conditions
- Interventions
- First Posted Date
- 2010-03-18
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT01089595
- Locations
- 🇺🇸
Siteman Cancer Center, Washington University School of Mediciine, St Louis, Missouri, United States
🇺🇸Wake Forest University, Winston-Salem, North Carolina, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Interventions
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT01077544
- Locations
- 🇬🇧
Novartis Investigative Site, Bristol, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.